Dynavax Technologies Corporation

12.17-0.3300-2.64%Vol 1.19M1Y Perf 34.55%
Jun 28th, 2022 16:00 DELAYED
BID11.90 ASK12.60
Open12.53 Previous Close12.50
Pre-Market- After-Market12.17
 - -  - -%
Target Price
32.00 
Analyst Rating
Strong Buy 1.00
Potential %
162.94 
Finscreener Ranking
★★★★     54.29
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     50.99
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     74.53
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
34.75 
Earnings Rating
Strong Sell
Market Cap1.54B 
Earnings Date
3rd Aug 2022
Alpha0.03 Standard Deviation0.28
Beta1.41 

Today's Price Range

12.0212.71

52W Range

7.2621.39

5 Year PE Ratio Range

-5.00-4.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
13.33%
1 Month
0.56%
3 Months
13.33%
6 Months
-11.97%
1 Year
34.55%
3 Years
213.28%
5 Years
23.15%
10 Years
-69.21%

TickerPriceChg.Chg.%
DVAX12.17-0.3300-2.64
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
1.40
2.00
0.47
0.90
14.40
Leverage Ratio 5.40
ProfitabilityValueIndustryS&P 500US Markets
59.50
25.00
26.50
-6 316.10
23.13
RevenueValueIndustryS&P 500US Markets
470.10M
3.72
179.57
192.05
Earnings HistoryEstimateReportedSurprise %
Q01 20220.240.22-8.33
Q04 20210.690.55-20.29
Q03 20210.050.0620.00
Q02 2021-0.040.02150.00
Q01 2021-0.020.01150.00
Q04 2020-0.24-0.1441.67
Q03 2020-0.20-0.1525.00
Q02 2020-0.24-0.27-12.50
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.22-18.52Negative
9/2022 QR0.30-18.92Negative
12/2022 FY1.14-7.32Negative
12/2023 FY0.02-92.31Negative
Next Report Date3rd Aug 2022
Estimated EPS Next Report0.22
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.19M
Shares Outstanding126.31K
Shares Float99.92M
Trades Count9.61K
Dollar Volume14.62M
Avg. Volume2.30M
Avg. Weekly Volume1.81M
Avg. Monthly Volume2.35M
Avg. Quarterly Volume2.73M

Dynavax Technologies Corporation (NASDAQ: DVAX) stock closed at 12.5 per share at the end of the most recent trading day (a 1.38% change compared to the prior day closing price) with a volume of 1.23M shares and market capitalization of 1.54B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 245 people. Dynavax Technologies Corporation CEO is Ryan Spencer.

The one-year performance of Dynavax Technologies Corporation stock is 34.55%, while year-to-date (YTD) performance is -11.16%. DVAX stock has a five-year performance of 23.15%. Its 52-week range is between 7.26 and 21.39, which gives DVAX stock a 52-week price range ratio of 34.75%

Dynavax Technologies Corporation currently has a PE ratio of 16.00, a price-to-book (PB) ratio of 5.42, a price-to-sale (PS) ratio of 3.36, a price to cashflow ratio of 7.10, a PEG ratio of 2.32, a ROA of 14.14%, a ROC of 25.22% and a ROE of 54.52%. The company’s profit margin is 23.13%, its EBITDA margin is 26.50%, and its revenue ttm is $470.10 Million , which makes it $3.72 revenue per share.

Of the last four earnings reports from Dynavax Technologies Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.22 for the next earnings report. Dynavax Technologies Corporation’s next earnings report date is 03rd Aug 2022.

The consensus rating of Wall Street analysts for Dynavax Technologies Corporation is Strong Buy (1), with a target price of $32, which is +162.94% compared to the current price. The earnings rating for Dynavax Technologies Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Dynavax Technologies Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Dynavax Technologies Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 23.32, ATR14 : 0.79, CCI20 : 77.05, Chaikin Money Flow : 0.03, MACD : 0.31, Money Flow Index : 67.61, ROC : -0.16, RSI : 61.36, STOCH (14,3) : 84.69, STOCH RSI : 1.00, UO : 61.28, Williams %R : -15.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Dynavax Technologies Corporation in the last 12-months were: Andrew A. F. Hack (Sold 2 250 000 shares of value $24 300 000 ), David Novack (Option Excercise at a value of $18 752), David Novack (Sold 80 000 shares of value $1 426 014 ), Francis R. Cano (Option Excercise at a value of $18 752), Justin Burgess (Option Excercise at a value of $76 200), Justin Burgess (Sold 31 768 shares of value $546 520 ), Peggy V. Phillips (Option Excercise at a value of $18 747), Robert Janssen (Option Excercise at a value of $1 230 043), Robert Janssen (Sold 222 805 shares of value $3 041 931 ), Ryan Spencer (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Dynavax Technologies Corporation

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax operates in the business segment the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.

CEO: Ryan Spencer

Telephone: +1 510 848-5100

Address: 2100 Powell Street, Emeryville 94608, CA, US

Number of employees: 245

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

52%48%

TipRanks News for DVAX

Mon, 25 Apr 2022 13:20 GMT Dynavax (DVAX) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Thu, 14 Apr 2022 13:25 GMT Dynavax (DVAX) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Wed, 12 Jan 2022 11:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Dynavax (DVAX), Phio Pharmaceuticals (PHIO) and Beyondspring (BYSI)

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 19:38 GMT Dynavax: Recent COVID-19 Approvals Leave Analysts Very Bullish

- TipRanks. All rights reserved.

News

Stocktwits